These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 11187864

  • 1. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 2. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K, Hermans C.
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [Abstract] [Full Text] [Related]

  • 3. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T, GTH PUP Study Group.
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [Abstract] [Full Text] [Related]

  • 4. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 5. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA, Levin LG, Harrison JA, DePianto DJ, Suzuki CM, Ziaja CL, Brown JE, Jolly KW, Reisner HM, Abildgaard CF, Powell JS.
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [Abstract] [Full Text] [Related]

  • 6. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.
    Semin Thromb Hemost; 1995 Feb; 21(4):382-9. PubMed ID: 8747701
    [Abstract] [Full Text] [Related]

  • 7. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM.
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [Abstract] [Full Text] [Related]

  • 8. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J.
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C, Dunkerley A, Sørensen B, Rangarajan S.
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [Abstract] [Full Text] [Related]

  • 10. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 11. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D, Reyes H, Felch M, Sakurai Y.
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [Abstract] [Full Text] [Related]

  • 12. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA, Recht M, Dipaola J, Shapiro AD, Pipe SW, Ewing N, Urgo J, Bullock T, Simmons M, Deguzman C.
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [Abstract] [Full Text] [Related]

  • 13. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

  • 14. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST, Addiego JE, Reason DC, Lucas AH.
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A.
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [Abstract] [Full Text] [Related]

  • 17. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, sippet study group.
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [Abstract] [Full Text] [Related]

  • 19. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.